What We Do

We are a bioscience company dedicated to improving glycemic health and healthy aging. Our team, which includes high-experienced and cited scientists, is pioneering research and development of Glo1 inducer supplements which correct insulin resistance in overweight and obese subjects and increase expression of Glo1 which is associated with healthy aging. We are the innovators behind Glo1 inducer food supplements. We patented our flagship supplement trans-resveratrol and hesperetin combination (tRES-HESP). This and related combinations are protected by our patent portfolio.

Glocentrica Ltd is a company registered in the United Kingdom, based in Kenilworth, West Midlands.


A person in a green suit speaking into a microphone

Description automatically generated
Professor Paul J Thornalley

A person wearing a head scarf

Description automatically generated
Professor Naila Rabbani, PhD

Executive Director

Professor Paul J Thornalley received his B.Sc. Chemistry from the University of Manchester, Manchester, U.K., in 1979 and D. Phil. Biochemistry in 1982 from University of Oxford, Oxford, U.K. He was Scientific Director, Diabetes Research Center, Qatar Biomedical Research Institute, Qatar, from 2018 – 2023 and is currently Adjunct Professor, College of Health & Life Sciences, Hamad Bin Khalifa University (HBKU), Doha, Qatar. 

He is a leading researcher in studies of the reactive glucose-derived metabolite, methylglyoxal, and its metabolism by glyoxalase 1 (Glo1) of the glyoxalase system – particularly in the development of insulin resistance and vascular complication of diabetes in which he is considered founding investigator.

In 1994, Thornalley led the first major clinical study showing exposure of patients with diabetes to profoundly increased levels of the reactive metabolite and glycating agent, methylglyoxal. In 2014, as Chief Investigating Office, he led the Healthy Aging Through Functional Food (HATFF or Hats-off) clinical trial of optimized Glo1 inducer food supplement, trans-resveratrol and hesperetin, finding that Glo1 inducer corrected insulin resistance in overweight and obese subjects.

In the past decade, he has led investigations into how increased methylglyoxal and other metabolic dysfunction drives development of glycemic disease – insulin resistance, pancreatic beta-cell failure, and the development of type 2 diabetes and related vascular complications. From this emerged the “Hexokinase-linked glycolytic overload and unscheduled glycolysis” hypothesis of glycemic disease and identification of increased methylglyoxal as major activator of the unfolded protein response.

Professional website


Professor Naila Rabbani received her B. Sc. Biological & Medicinal Chemistry in 1998 and PhD Biochemistry in 2002 from University of Essex, Colchester, U.K. She is currently Adjunct Professor of Basic Medical Sciences, College of Medicine, Qatar. She is a biomedical research scientist with over 25 years’ experience in clinical translational research. She is a leading international expert in protein glycation research in which she developed the AGEomics technology and pioneered the application of artificial intelligence (AI) machine learning for the development of diagnostic algorithms with protein glycation biomarkers as features.

In 2014, Rabbani, then faculty member at Warwick Medical School, led protein glycation analysis in the Healthy Aging Through Functional Food clinical trial of glyoxalase 1 (Glo1) inducer, trans-resveratrol and hesperetin, finding that Glo1 inducer decreased protein glycation by methylglyoxal and metabolism-linked low-grade inflammation, and corrected insulin resistance in overweight and obese subjects.

In the past decade, Professor Rabbani has made multiple seminal contributions to the causes and consequences of increased methylglyoxal concentration, dicarbonyl stress, and related protein glycation – including its origin in insulin resistance, beta-cell glucotoxicity and diabetes, consequences for increased metabolic stress and inflammation through activation of the unfolded protein response, and methylglyoxal protein glycation adducts as diagnostic indicators of glycemic disease.

Achievements of Directors

Over 40 years of pioneering experience and expertise in dysfunction glucose metabolism in insulin resistance, obesity, diabetes, related vascular complications of diabetes, other disease and disorders and aging

Founding research and development of physiological formation, metabolism and function of reactive metabolite methylglyoxal

Over 40 years of Award-Winning Excellence in Academic Research

Glocentrica Ltd created as a spinout company in 2019

Directors are highly accomplished scientists:

Professor Paul J Thornalley has published 327 Peer-Reviewed Publications, including 10+ Clinical Studies and 4 Industry Awards. Google scholar
Professor Rabbani has published 156 Peer-Reviewed Publications, including 10+ Clinical Studies and 4 Industry Awards. Google Scholar